All Satellite Symposia, Presentation Theaters, and Learning Lounges preceding and following the official program IDWeek 2016 are independently organized and executed. IDWeek does not endorse or support the programming of any Symposia, Presentation Theater, or Learning Lounge.
Atul Humar, MD (Chair)
Director, Multi-Organ Transplant Program
University Health Network, Toronto, ON
Michael Boeckh, MD, PhD
Fred Hutchinson Cancer Research Center
University of Washington, Seattle, WA
Sunwen Chou, MD
Professor of Medicine
Oregon Health & Science University, Portland, OR
Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Massachusetts General Hospital
Harvard Medical School
Past Chair, Infectious Disease Community of Practice, American Society of Transplantation, Boston, MA
This activity has been designed to meet the educational needs of clinicians who manage transplant patients with cytomegalovirus.
After completing this activity, the participant should be better able to:
Outline the burden of CMV viremia in SOT and HSCT patients including unmet needs for improved therapies
Describe the mechanisms and clinical implications of CMV drug resistance and refractory CMV disease
Summarize clinical trial data for emerging antiviral therapies
Integrate existing and emerging antiviral therapies into the treatment of CMV infection and/or disease in SOT and HSCT patients
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
Agenda subject to change and was provided by:
RMEI Medical Education, LLC; 101 Laurel Road, Suite, 200; Voorhees, NJ; Phone: 856-672-3300; Fax: 856-546-7030
Please contact Stephanie Kielt directly at email@example.com for more information.